Masonic Cancer Center, University of Minnesota
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Masonic Cancer Center, University of Minnesota sits in the top decile of US sponsors by registered trial count (#132 of 15,742 sponsors by registered trial count).
Masonic Cancer Center, University of Minnesota: 249 sponsored US clinical trials, 36 recruiting.
Masonic Cancer Center, University of Minnesota sponsors 249 registered US clinical trials on ClinicalTrials.gov, 36 of them currently recruiting, and 127 completed. 1 of these trials are in Phase 3-4 (later-stage) and 183 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Acute Myeloid Leukemia, with 7 trials.
Top-decile sponsor footprint
Masonic Cancer Center, University of Minnesota ranks in the top decile of sponsors by registered trial count (#132 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
127 of 201 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (63.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
249 total, page 3 of 5
Naglazyme After Allo Transplant for Maroteaux-Lamy Syndrome
NCT02156674
HM2014-26 DT2219 for Relapsed or Refractory B-Lineage Leukemia or Lymphoma
NCT02370160
Investigation of Kava Effects on NNK Metabolism
NCT02500472
MT2014-25: Haplo NK With SQ IL-15 in Adult Relapsed or Refractory AML Patients
NCT02395822
Negative Pressure Wound Therapy in Obese Gynecologic Oncology Patients
NCT02309944
Safety of Romiplostim (Nplate®) Following UCBT
NCT02046291
Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation
NCT02074631
MT2013-37R: Voriconazole Monitoring in Pediatric Stem Cell Transplant Patients
NCT02227797
Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia
NCT02162420
Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases
NCT02145039
Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies
NCT02179359
Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
NCT02118285
ADAM17 Inhibitor/ Rituximab After Auto HCT for DLBCL
NCT02141451
Pilot Study of Multi-Modality Imaging in Patients With Hematologic Malignancies
NCT02042924
DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma
NCT00889408
MIBG for Refractory Neuroblastoma and Pheochromocytoma
NCT01850888
AHN-12 Biodistribution in Advanced Leukemia
NCT01207076
IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT
NCT01885897
Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation
NCT01634217
Vegetable Intake Effect on Heterocyclic Amine Metabolism
NCT04882423
Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes
NCT01593670
Implementation of a Rapid Recovery Program in Gynecologic Oncology Surgery: A Pilot Study
NCT01705288
Busulfan and Cyclophosphamide Followed By ALLO BMT
NCT01685411
Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer
NCT01560923
Total Marrow Irradiation for Refractory Acute Leukemia
NCT00686556
Imiquimod/Brain Tumor Initiating Cell (BTIC) Vaccine in Brain Stem Glioma
NCT01400672
Reduced-Intensity Hematopoietic Stem Cell Transplant for High Risk Lysosomal and Peroxisomal Disorders
NCT01626092
Cancer and Mindfulness-Based Cancer Recovery After Chemotherapy
NCT01601548
Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer
NCT01581970
Administration of IV Laronidase Post Bone Marrow Transplant in Hurler
NCT01173016
Biomarker Feedback for Smoking Cessation
NCT02206971
High Dose Chemotherapy and Autologous Transplant for Neuroblastoma
NCT01526603
Laronidase (Aldurazyme TM) Enzyme Replacement Therapy With Hematopoietic Stem Cell Transplant for Hurler Syndrome
NCT01572636
Auto Transplant for High Risk or Relapsed Solid or CNS Tumors
NCT01505569
T-Cell Depleted Double UCB for Refractory AML
NCT01464359
NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases
NCT01370213
Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML)
NCT01385423
Preservation of Ovarian Function After Hematopoietic Cell Transplant
NCT01343368
Selecting a Favorable KIR Donor in Unrelated HCT for AML
NCT01288222
Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)
NCT01312818
Metabolism of NNK Among African Americans
NCT01158456
Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor
NCT01171469
Influenza Vaccine Post Allogeneic Transplant
NCT01215981
Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy
NCT01056601
Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies
NCT01181258
WCC# 59 Hyperthermic Intraperitoneal Chemotherapy Utilizing Carboplatin in First Recurrence Ovarian Cancer
NCT01144442
Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer
NCT01105650
Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML)
NCT01106950
Ritonavir and Its Effects on Biomarkers in Women Undergoing Surgery for Newly Diagnosed Breast Cancer
NCT01009437
IL-2 Expressing, Attenuated Salmonella Typhimurium in Unresectable Hepatic Spread
NCT01099631
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 76 |
| Phase 2 | 107 |
| Phase 3 | 1 |
What is open in the Masonic Cancer Center, University of Minnesota pipeline
36 recruiting of 249 indexed (14% open); 127 completed (51%).
Phase mix: 1 late (III/IV) vs 183 early (I/II) (early-phase heavy).
Top condition: Acute Myeloid Leukemia (7 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Masonic Cancer Center, University of Minnesota: open-pipeline peers nationwide
Peers matched on 249 registered trials and 14% open enrollment, not the therapeutic-area sidebar.
Masonic Cancer Center, University of Minnesota sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 249 trials (± recruiting share)
- University of South Florida · 252 trials · 17% recruiting
- Boston Medical Center · 253 trials · 11% recruiting
- Shire · 245 trials · 0% recruiting
- University of Cincinnati · 245 trials · 14% recruiting
Sponsors near 14% open enrollment (± trial volume)
- ModernaTX · 14% recruiting · 90 trials
- The Cleveland Clinic · 14% recruiting · 688 trials
- University of Wisconsin, Madison · 15% recruiting · 1,039 trials
- Dana-Farber Cancer Institute · 14% recruiting · 781 trials
Related
What to do with this Masonic Cancer Center, University of Minnesota page
249 registered trials is a research-attention snapshot, not an endorsement of Masonic Cancer Center, University of Minnesota or any single study.
- 36 of Masonic Cancer Center, University of Minnesota's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Acute Myeloid Leukemia is the condition Masonic Cancer Center, University of Minnesota studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Acute Myeloid Leukemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Masonic Cancer Center, University of Minnesota pipeline card: 249 registered trials from official public datasets.Report a data error.